Basics |
Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical stage biopharmaceutical company. The company is engaged in drug research and development to create new therapies for fibrotic disease and cancer.
|
IPO Date: |
October 1, 2002 |
Sector: |
Healthcare |
Industry: |
Biotech |
Market Cap: |
$177.22M |
Activated in VL: |
True |
Average Daily Range |
Avg Daily Range: |
$0.14 | 3.90%
|
Avg Daily Range (30 D): |
$0.18 | 7.52%
|
Avg Daily Range (90 D): |
$0.10 | 5.39%
|
Institutional Daily Volume |
Avg Daily Volume: |
.33M |
Avg Daily Volume (30 D): |
.86M |
Avg Daily Volume (90 D): |
.4M |
Trade Size |
Avg Trade Size (Sh.): |
243 |
Avg Trade Size (Sh.) (30 D): |
196 |
Avg Trade Size (Sh.) (90 D): |
181 |
Institutional Trades |
Total Inst.Trades: |
48 |
Avg Inst. Trade: |
$1.95M |
Avg Inst. Trade (30 D): |
$1.87M |
Avg Inst. Trade (90 D): |
$1.23M |
Avg Inst. Trade Volume: |
.4M |
Avg Inst. Trades (Per Day): |
1 |
Market Closing Trades |
Avg Closing Trade: |
$3.81M |
Avg Closing Trade (30 D): |
$1.87M |
Avg Closing Trade (90 D): |
$1.45M |
Avg Closing Volume: |
908.96K |
|
|
Financials |
|
TTM |
Q1 2025 |
Q4 2024 |
Basic EPS
|
$-.72
|
$-.15
|
$-.19
|
Diluted EPS
|
$-.72
|
$-.15
|
$-.19
|
Revenue
|
$ M
|
$ M
|
$ M
|
Gross Profit
|
$
|
$
|
$
|
Net Income / Loss
|
$ -45.19M
|
$ -9.63M
|
$ -11.97M
|
Operating Income / Loss
|
$ -40.68M
|
$ -7.9M
|
$ -12.43M
|
Cost of Revenue
|
$
|
$
|
$
|
Net Cash Flow
|
$ -7.69M
|
$ -7.69M
|
$ M
|
PE Ratio
|
|
|
|
|
|
|